Abstract:Nanomotors offer a new approach to treating inflammation‐related diseases. They actively target inflammation sites, control drug release, and improve treatment efficacy. Compared to traditional treatments and static nanomaterials, nanomotors have advantages in reducing side effects and costs. Inflammation is a physiological response of the body to harmful stimuli such as pathogens, damaged cells, or irritants, involving a series of cellular and molecular events. It is associated with various diseases including neurodegenerative disorders, cancer, and atherosclerosis, and is a leading cause of global mortality. Key inflammatory factors, such as Tumor Necrosis Factor‐alpha (TNF‐α), Interleukin‐1 (IL‐1), Interleukin‐6 (IL‐6), Monocyte Chemoattractant Protein‐1 (MCP‐1/CCL2), RANTES (CCL5), and prostaglandins, play central roles in inflammation and disease progression. Traditional treatments such as NSAIDs, steroids, biologic agents, and antioxidants have limitations. Recent advancements in nanomaterials present promising solutions for treating inflammation‐related diseases. Unlike nanomaterials that rely on passive targeting and face challenges in precise drug delivery, nanomotors, driven by chemical or optical stimuli, offer a more dynamic approach by actively navigating to inflammation sites, thereby enhancing drug delivery efficiency and therapeutic outcomes. Nanomotors allow for controlled drug release in response to specific environmental changes, such as pH and inflammatory factors, ensuring effective drug concentrations at disease sites. This active targeting capability enables the use of smaller drug doses, which reduces overall drug usage, costs, and potential side effects compared to traditional treatments. By improving precision and efficiency, nanomotors address the limitations of conventional therapies and represent a significant advancement in the treatment of inflammation‐related diseases. This review summarizes the latest research on nanomotor‐mediated treatment of inflammation‐related diseases and discusses the challenges and future directions for optimizing their clinical translation.

Engineering Cell Membrane‐Based Nanotherapeutics to Target Inflammation

Nanotherapeutics: Engineering Cell Membrane‐Based Nanotherapeutics to Target Inflammation (adv. Sci. 15/2019)

Recent Advances of Engineered Cell Membrane-Based Nanotherapeutics to Combat Inflammatory Diseases.

Neutrophil‐Based Delivery Systems for Nanotherapeutics

Nanotechnology-Mediated Immunomodulation Strategy for Inflammation Resolution

Neutrophils and Macrophages as Targets for Development of Nanotherapeutics in Inflammatory Diseases

Nanomotors as Therapeutic Agents: Advancing Treatment Strategies for Inflammation‐Related Diseases

Nanotechnology Reinforced Neutrophil-Based Therapeutic Strategies for Inflammatory Diseases Therapy

Biomimetic Nanoparticles for Inflammation Targeting

Fibroblast membrane-camouflaged nanoparticles for inflammation treatment in the early stage

Development of nanoparticle‐based drug delivery system for inflammation treatment and diagnosis

Cell Membrane Biomimetic Nanoparticles for Inflammation and Cancer Targeting in Drug Delivery.

Cell-membrane engineering strategies for clinic-guided design of nanomedicine

Cell Membrane-Formed Nanovesicles for Disease-Targeted Delivery.

Bioinspired membrane-based nanomodulators for immunotherapy of autoimmune and infectious diseases

Targeted therapies of inflammatory diseases with intracellularly gelated macrophages in mice and rats

Harnessing anti-inflammatory pathways and macrophage nano delivery to treat inflammatory and fibrotic disorders

Macrophage-Biomimetic Nanoplatform-Based Therapy for Inflammation-Associated Diseases.

Cell Membrane-Coated Nanotherapeutics for the Targeted Treatment of Acute and Chronic Colitis

Anti‐Inflammatory Nanotherapies Based on Bioactive Cyclodextrin Materials

Engineering of Biodegradable and Excretable Inflammation‐Resolving Materials